Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma.
hepatocellular carcinoma (HCC) is the most common primary liver cancer and remains difficult to treat in advanced stages because of tumor heterogeneity and an immunosuppressive microenvironment. After acute antigen exposure, anti-GPC3 CAR4 T-cells showed lower PD-1 and higher TIM-3 than anti-GPC3 CAR2 T-cells.
hepatocellular carcinoma (HCC) is the most common primary liver cancer and remains difficult to treat in advanced stages because of tumor heterogeneity and an immunosuppressive microenvironment. After acute antigen exposure, anti-GPC3 CAR4 T-cells showed lower PD-1 and higher TIM-3 than anti-GPC3 CAR2 T-cells.
What the study was
- Study design
- Validation study
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Why it surfaced
Low-signal Novel therapeutics: immunotherapy, CAR-T, targeted therapy entry (Validation study design); retained for topic coverage completeness.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.